Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T22:46:50.667Z.
Calculation as of: 2026-10-06T22:46:50.667Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 76b79f67d555c15c1d19b9a53ec9076b1294dcb64452140a50102a9ec63499e7
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$8.33M
Price/OCF Ratio
N/A
TTM Avg
9.84
3Y Avg
9.84
5Y Avg
9.84
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | $8.04M | N/A | N/A | N/A | N/A |
| DataMEDS AI, Inc. (MEDS)vs › | $8.05M | N/A | N/A | N/A | N/A |
| HeartSciences Inc. (HSCS)vs › | $8.14M | N/A | N/A | N/A | N/A |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | N/A | N/A | N/A | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.87M | N/A | N/A | N/A | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.33M | N/A | 9.84 | 9.84 | 9.84 |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | N/A | N/A | N/A | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.67M | N/A | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.64M | N/A | N/A | N/A | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.46M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
